{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:26:01Z","timestamp":1790641561847,"version":"4.1.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Autoimmune anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) and glomerulonephritis is characterized by the presence of autoantibodies (so-called ANCA), which, by binding to the body\u2019s own antigens, lead to damaged blood vessels (vasculitis) and subsequently to organ damage, particularly of the kidneys. The primary endogenous antigens are the enzymes proteinase 3 (PR3) and myeloperoxidase (MPO) expressed by neutrophil granulocytes and monocytes. In addition to the autoantibodies, both T-cellular response to those autoantigens and monocyte\/macrophage-mediated processes play a decisive role. Since conventional therapy is based on the widespread suppression of the immune system, susceptibility to infections or the development of cancer are possible side effects. Furthermore, not all patients respond to conventional therapy or, despite responding at first, suffer multiple relapses. Therefore, there is a need for alternative treatment strategies and one promising option is the use of CD19-targeting chimeric antigen receptor (CAR)-T cells.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf290","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:45:44Z","timestamp":1758023144000},"page":"ii35-ii46","source":"Crossref","is-referenced-by-count":5,"title":["CAR-T cells targeting CD19 for the treatment of ANCA vasculitis"],"prefix":"10.1093","volume":"18","author":[{"given":"D\u00f6rte","family":"Lodka","sequence":"first","affiliation":[{"name":"Experimental and Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6379","authenticated-orcid":false,"given":"Adrian","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association , Berlin ,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Department of Nephrology and Medical Intensive Care, , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2025121209163808000_bib1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00281-014-0431-y","article-title":"B cell-mediated pathogenesis of ANCA-mediated vasculitis","volume":"36","author":"Jennette","year":"2014","journal-title":"Semin Immunopathol"},{"key":"2025121209163808000_bib2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0140-6736(85)91147-X","article-title":"Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in wegener\u2019s granulomatosis","volume":"325","author":"Van Der Woude","year":"1985","journal-title":"Lancet"},{"key":"2025121209163808000_bib3","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1182\/blood-2005-05-1875","article-title":"Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway","volume":"107","author":"Csernok","year":"2006","journal-title":"Blood"},{"key":"2025121209163808000_bib4","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025121209163808000_bib5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2796.1998.00357.x","article-title":"Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies","volume":"244","year":"1998","journal-title":"J Intern Med"},{"key":"2025121209163808000_bib7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3899\/jrheum.131038","article-title":"A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)\u2013associated nephritis versus myeloperoxidase ANCA\u2013associated nephritis","volume":"41","author":"Mohammad","year":"2014","journal-title":"J Rheumatol"},{"key":"2025121209163808000_bib8","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1016\/j.ekir.2022.09.011","article-title":"Relevance of combined clinicopathologic phenotype and antineutrophil cytoplasmic autoantibody serotype in the diagnosis of antineutrophil cytoplasmic autoantibody vasculitis","volume":"7","author":"Alba","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025121209163808000_bib9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","article-title":"Interstital lung disease in ANCA vasculitis","volume":"16","author":"Alba","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025121209163808000_bib10","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1681\/ASN.2014090903","article-title":"Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis","volume":"26","author":"Hilhorst","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163808000_bib11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"2025121209163808000_bib12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody\u2013associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121209163808000_bib13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/1529-0131(200104)44:4%3c921::AID-ANR149%3e3.0.CO;2-4","article-title":"IgG from myeloperoxidase\u2013antineutrophil cytoplasmic antibody\u2013positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3\u2013antineutrophil cytoplasmic antibody\u2013positive patients","volume":"44","author":"Harper","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2025121209163808000_bib14","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/art.10384","article-title":"In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase","volume":"46","author":"Popa","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025121209163808000_bib15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/MOH.0000000000000098","article-title":"The role of neutrophils in causing antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"22","author":"Schreiber","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"2025121209163808000_bib16","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.ajpath.2017.05.003","article-title":"Monocytes promote crescent formation in anti-myeloperoxidase antibody\u2013induced glomerulonephritis","volume":"187","author":"Rousselle","year":"2017","journal-title":"Am J Pathol"},{"key":"2025121209163808000_bib17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1681\/ASN.2010080892","article-title":"Neutrophil serine proteases promote IL-1\u03b2 generation and injury in necrotizing crescentic glomerulonephritis","volume":"23","author":"Schreiber","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163808000_bib18","doi-asserted-by":"crossref","first-page":"E9618","DOI":"10.1073\/pnas.1708247114","article-title":"Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis","volume":"114","author":"Schreiber","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025121209163808000_bib19","doi-asserted-by":"publisher","first-page":"E2615","DOI":"10.1073\/pnas.1210147109","article-title":"The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis","volume":"109","author":"Ooi","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025121209163808000_bib20","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41467-019-11255-0","article-title":"A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity","volume":"10","author":"Ooi","year":"2019","journal-title":"Nat Commun"},{"key":"2025121209163808000_bib21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol Rev"},{"key":"2025121209163808000_bib22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025121209163808000_bib23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121209163808000_bib24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163808000_bib25","doi-asserted-by":"publisher","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"2025121209163808000_bib26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib27","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2007.071936","article-title":"Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force","volume":"67","author":"Mukhtyar","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib30","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib31","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025121209163808000_bib32","doi-asserted-by":"publisher","first-page":"e083277","DOI":"10.1136\/bmjopen-2023-083277","article-title":"Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas","volume":"14","author":"McGovern","year":"2024","journal-title":"BMJ Open"},{"key":"2025121209163808000_bib33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"2025121209163808000_bib34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121209163808000_bib35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib36","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"2025121209163808000_bib37","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"2025121209163808000_bib38","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"2025121209163808000_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front Immunol"},{"key":"2025121209163808000_bib40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Cartellieri","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"2025121209163808000_bib41","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.bulcan.2021.02.017","article-title":"CAR-T cells, from principle to clinical applications","volume":"108","author":"Bourbon","year":"2021","journal-title":"Bull Cancer"},{"key":"2025121209163808000_bib42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"2025121209163808000_bib43","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025121209163808000_bib44","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2025121209163808000_bib45","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025121209163808000_bib46","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121209163808000_bib47","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2025121209163808000_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"2025121209163808000_bib49","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib50","doi-asserted-by":"publisher","first-page":"103692","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"2025121209163808000_bib51","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"2025121209163808000_bib52","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"2025121209163808000_bib53","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"2025121209163808000_bib54","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025121209163808000_bib55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren\u2019s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"key":"2025121209163808000_bib56","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"2025121209163808000_bib57","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"key":"2025121209163808000_bib58","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib59","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"2025121209163808000_bib60","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib62","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/bjh.16266","article-title":"Chimeric antigen receptor T-cell therapy\u2019s role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br J Haematol"},{"key":"2025121209163808000_bib63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"2025121209163808000_bib64","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib65","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib66","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ard.2025.04.029","article-title":"Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis","volume":"84","author":"Uhlmann","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib67","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.ekir.2025.05.016","article-title":"Point-of-care anti\u2013CD19-CAR T-cell therapy induces renal remission in refractory myeloperoxidase\u2013antineutrophil cytoplasmic autoantibody\u2013associated vasculitis","volume":"10","author":"Schultze-Florey","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2025121209163808000_bib68","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/rheumatology\/kead616","article-title":"Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases","volume":"63","author":"Lyu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025121209163808000_bib69","doi-asserted-by":"publisher","first-page":"eado2084","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci Transl Med"},{"key":"2025121209163808000_bib70","doi-asserted-by":"publisher","first-page":"152479","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies\u2014evidence, safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025121209163808000_bib71","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","article-title":"Barriers to CAR T-cell therapy in rheumatology","volume":"7","author":"Lungova","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2025121209163808000_bib72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10067-025-07451-7","article-title":"CAR-T cell therapy in rheumatic diseases: a review article","author":"Patil","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2025121209163808000_bib73","doi-asserted-by":"publisher","first-page":"0712","DOI":"10.34133\/research.0712","article-title":"Revolutionizing autoimmune kidney disease treatment with chimeric antigen receptor-T cell therapy","volume":"8","author":"Gu","year":"2025","journal-title":"Research (Wash D C)"},{"key":"2025121209163808000_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2025121209163808000_bib75","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121209163808000_bib76","doi-asserted-by":"publisher","first-page":"sfae123","DOI":"10.1093\/ckj\/sfae123","article-title":"Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes","volume":"17","author":"Vincendeau","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025121209163808000_bib77","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121209163808000_bib78","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bulcan.2022.08.014","article-title":"Acute kidney injury after CAR-T cell infusion","volume":"111","author":"Rousseau","year":"2024","journal-title":"Bull Cancer"},{"key":"2025121209163808000_bib79","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"2025121209163808000_bib80","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2025121209163808000_bib81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025121209163808000_bib82","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"2025121209163808000_bib83","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1007\/s12015-025-10923-7","article-title":"Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-year follow-up","volume":"21","author":"Wang","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"2025121209163808000_bib84","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"2025121209163808000_bib85","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"2025121209163808000_bib86","doi-asserted-by":"publisher","first-page":"e003464","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"2025121209163808000_bib87","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2025121209163808000_bib88","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2025121209163808000_bib89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"2025121209163808000_bib90","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.tranon.2024.102147","article-title":"Universal CAR cell therapy: challenges and expanding applications","volume":"51","author":"Wu","year":"2025","journal-title":"Transl Oncol"},{"key":"2025121209163808000_bib91","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat Commun"},{"key":"2025121209163808000_bib92","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025121209163808000_bib93","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell\u2013mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"2025121209163808000_bib94","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121209163808000_bib95","first-page":"e65291","article-title":"Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence","volume":"16","author":"Ghorai","year":"2024;","journal-title":"Cureus"},{"key":"2025121209163808000_bib96","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025121209163808000_bib97","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"2025121209163808000_bib98","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"2025121209163808000_bib99","doi-asserted-by":"publisher","first-page":"e006292","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025121209163808000_bib100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"2025121209163808000_bib101","doi-asserted-by":"publisher","first-page":"2304378","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"2025121209163808000_bib102","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2024.1335424","article-title":"Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic","volume":"15","author":"Smirnov","year":"2024","journal-title":"Front Immunol"},{"key":"2025121209163808000_bib103","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fonc.2022.832765","article-title":"Special Chimeric antigen receptor (CAR) modifications of T cells: a review","volume":"12","author":"Miao","year":"2022","journal-title":"Front Oncol"},{"key":"2025121209163808000_bib104","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121209163808000_bib105","first-page":"8","article-title":"Ligand-based CAR-T cell: different strategies to drive T cells in future new treatments","volume":"13","author":"Ram\u00edrez-Chac\u00f3n","year":"2022","journal-title":"Front Immunol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf290\/64464485\/sfaf290.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii35\/64464485\/sfaf290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii35\/64464485\/sfaf290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:16:45Z","timestamp":1765549005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/18\/Supplement_2\/ii35\/8270678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":105,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf290","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,1]]}}}